A Phase II Evaluation Of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC 704865, IND 7921) In The Treatment of Persistent Or Recurrent Epithelial Ovarian Or Primary Peritoneal Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 24 Jul 2019 Biomarkers information updated
- 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 19 Sep 2005 New trial record.